A UK pharmaceutical company has announced positive results in a study of a new drug that could be used to treat Parkinson's disease.
Vernalis has been studying the effects of the drug, V81444, since August to examine the effect it has on receptors in the brain that relate to Parkinson's disease.
The study used MRI and positron emission tomography scans to assess the progress of the drug and the company has concluded that the trial was successful.
Versalis stated that the drug could achieve a "full blockade" of the adenosine receptor - which has long been believed to be integral in the treatment of Parkinson's - with doses within guidelines that pose "no safety concerns".
Ian Garland, CEO of Vernalis said: “We are very pleased with these results and are already actively preparing for the continued development of this exciting program over the next 12 months.”
The company will now conduct a further proof-of-concept study to show the drug could be used in Parkinson's disease treatments.